What Is Being Watched: LifePoint Health (NASDAQ:LPNT), Quaker Chemical Corporation (NYSE:KWR), Dish Network Corp. (NASDAQ:DISH), Progenics Pharmaceuticals (NASDAQ:PGNX), Mirati Therapeutics (NASDAQ:MRTX)

LifePoint Health, Inc. (NASDAQ:LPNT) shares advanced 2.27% in last trading session and ended the day at $79.58. LPNT Gross Margin is 36.30% and its has a return on assets of 2.50%. LifePoint Health, Inc. (NASDAQ:LPNT) quarterly performance is 8.05%.

LifePoint Health (LPNT) is a leading healthcare company dedicated to Making Communities Healthier®. Through its subsidiaries, it provides quality inpatient, outpatient and post-acute services close to home. LifePoint owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in 21 states.

LifePoint Health, Inc. (NASDAQ:LPNT) announced that its management will participate in the 2015 Wells Fargo Healthcare Conference to be held September 9 – 10, 2015, in Boston, MA. The Company also announced that a live broadcast of the presentation will be available on Thursday, September 10, 2015, beginning at 1:55 p.m. Eastern Time.

Quaker Chemical Corporation (NYSE:KWR) ended the last trading day at $78.97. Company weekly volatility is calculated as 3.09% and price to cash ratio as 16.01. Quaker Chemical Corporation (NYSE:KWR) showed a weekly performance of -0.49%.

Quaker Chemical is a leading global provider of process fluids, chemical specialties, and technical expertise to a wide range of industries, including steel, aluminum, automotive, mining, aerospace, tube and pipe, cans, and others.

Quaker Chemical Corporation (NYSE:KWR) announced that Margaret M. Loebl has resigned from her position as Vice President, Chief Financial Officer and Treasurer of Quaker effective September 18, 2015. Ms. Loebl has accepted the position of Executive Vice President and Chief Financial Officer at AgroFresh Solutions (AGFS), a specialty solutions company based in Philadelphia. Quaker has begun the search for a new CFO.

On 08 September, Dish Network Corp. (NASDAQ:DISH) shares advanced 2.75% and was closed at $60.55. DISH EPS growth in last 5 year was 7.50%. Dish Network Corp. (NASDAQ:DISH) year to date (YTD) performance is -16.93%.

On 25 August, it was reported Despite reaching an agreement on rates and all other terms for the carriage of the Sinclair local stations, DISH Network Corp. (NASDAQ:DISH) said that this afternoon Sinclair Broadcast Group, Inc. chose to begin the largest local channel blackout in the history of television, blocking DISH customers’ access to 129 local channels in 79 markets across 36 states and the District of Columbia, and intentionally harming and exploiting millions of innocent consumers to gain negotiating leverage for carriage of an unrelated cable channel that it hopes to acquire but does not own.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares advanced 0.87% in last trading session and ended the day at $6.93. PGNX Gross Margin is 99.10% and its has a return on assets of -11.20%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) quarterly performance is 12.87%.

Progenics Pharmaceuticals, Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra.

Needham & Company LLC reissued their buy rating on shares of Progenics Pharmaceuticals (NASDAQ:PGNX) in a research note issued to investors on Friday, MarketBeat.com reports. The firm currently has a $11.00 price target on the stock, up from their previous price target of $9.00.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) caters to the Healthcare space. Its weekly performance is 8.44%. On the last day of trading company shares ended up $28.00. Mirati Therapeutics, Inc. (NASDAQ:MRTX) distance from 50-day simple moving average (SMA50) is 0.57%.

Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. Mirati’s approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished targeted oncology leadership team.

Mirati Therapeutics, Inc. (NASDAQ:MRTX), announced it will present data on its two tyrosine kinase inhibitors, MGCD265 and MGCD516, at the International Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer being held in Denver, CO from September 6-9, 2015.